Navigation Links
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
Date:10/27/2008

signed to achieve a non-inferiority margin of 10% for ceftaroline versus the comparator regimen for the above endpoints. The most common infections included deep, extensive cellulitis and major abscesses. The percent of patients with diabetes and peripheral vascular disease in the ceftaroline arm was 17.7% and 13.4%, respectively.(1) 30% of patients with a confirmed pathogen had a MRSA infection.

The most common pathogens isolated were S. aureus (MSSA and MRSA), Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, E. coli and P. aeruginosa. A comprehensive microbiological investigation was completed and ceftaroline demonstrated activity against a broad range of gram-positive pathogens and gram-negative pathogens. Microbiological eradication rates for ceftaroline alone were similar to those of the combination of vancomycin plus aztreonam (91.8% vs. 92.5%). MRSA eradication rates were also similar in the microbiologically evaluable patients in the ceftaroline and combination arms (94.9% vs. 91.8%).

"These new data add to the growing scientific evidence that support ceftaroline as a potential novel treatment for cSSSIs, including those caused by MRSA," said G. Ralph Corey, MD, Director, Infectious Diseases, Duke Clinical Research Institute. "These results are important because we see a growing number of infections, including many with difficult-to-treat organisms. Clearly new options are needed to optimize our current treatment capabilities."

The results of CANVAS I also demonstrate that ceftaroline was well tolerated. The majority of adverse events reported were mild and judged to be not treatment related. The percentage of patients who experienced an adverse event was similar in both treatment groups. The most common adverse events observed in the ceftaroline vs. vancomycin-plus-aztreonam arms were nausea (5.7% vs. 4.6%), headache (5.1% vs. 3.7%) and pruritis (3.1% vs. 8.4%).(1)

The data presented from CANVAS I demonstr
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
2. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
3. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
4. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Kuvan Receives Positive Opinion From CHMP for European Approval
9. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
10. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
11. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... ... 2015 , ... GEA's Pony™ NS2006L is a ... to 1500 bar. The sanitary design gauge of the NS2006L is well suited ... Pony™ NS2006L homogenizer is an ideal solution for the processing of nanoparticles, ...
(Date:7/29/2015)... +14% CER / 20% of sales) led the regional performance in the second ... well as solid contributions from Korea, India and ... East / Africa (Q2 2015: +3% CER ... Turkey and the United Kingdom . The ... HPV sales, on demand across all customer classes. The top seven emerging markets ...
(Date:7/29/2015)... , July 29, 2015 ... has announced the addition of the "Global ... their offering. The Global Biosimilars Market, ... of the rapidly growing biosimilars market. With the ... striving to minimize costs, biosimilars are being viewed ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3
... Technologies, Inc. (NYSE Amex: PTN ), a biopharmaceutical ... acute asthma and other indications, today announced results for its ... Recent Highlights Following a meeting with ... revised protocol to the FDA for initiation of an at-home ...
... (slow down) in a well-understood linear manner, but ground-breaking ... at the Catalan Institute of Nanotechnology has shown that ... nonlinear damping, opening up exciting possibilities for super-sensitive detectors ... be published in Nature Nanotechnology (DOI - ...
... 13, 2011 TEI Biosciences Inc. was named ... by the Smaller Business Association of New England (SBANE) ... one of six winners in the for-profit category. ... including technology, manufacturing, service and retail/distribution, and include Genzyme, Staples, ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 2Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 3Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 4Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 5Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results 6Exotic behavior when mechanical devices reach the nanoscale 2TEI Biosciences Wins SBANE 2011 New England Innovation Award 2
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... Florida , July 8, 2015 ... evolving as this summer,s must have products such as wearables, ... demand as popularity for biometrics based devices continues to rapidly ... NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ) ...
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... Bureau of Land Management,s (BLM) current practice of removing ... growth rate, and maintaining them in long-term holding facilities ... says a new report by the National Research Council. ... BLM to better manage horses and burros on healthy ...
... research suggests that infants fed formula, rather than breast milk, ... long-recognized link between formula-feeding and an increased risk of obesity, ... study appears in ACS, Journal of Proteome Research . ... a link between formula-feeding and a higher risk for chronic ...
... School of Medicine (BUSM) have uncovered important clues about ... day expand treatment options for schizophrenia. The study, published ... led by faculty within the department of pharmacology and ... from a life-long condition that can produce delusions, disordered ...
Cached Biology News:New report offers science-based strategies for management of western free-ranging horses and burros 2Neurochemical traffic signals may open new avenues for the treatment of schizophrenia 2
Supplemental reagent for annexin V assay....
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Ultra-sensitive, non-radioactive detection of rat Big Endothelin-1 (Big ET-1)...
... Peptide Antigen Design , Customer Peptide Synthesis , ... above 90% , 20 mg will return to customer ... Rabbits x 2 , Maintenance 102 days/each ... Immunizations/Boost injections x5 /each , Test ...
Biology Products: